ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL
Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.
United States Genentech Roche Morphosys Incyte Jason Westin Lymphoma Clinical Research Program Janssen Scientific Affairs
Source: onclive.com